医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Cantargia AB: Cantargia Receives Patent Approval in Japan and Mexico

2016年03月21日 PM04:45
このエントリーをはてなブックマークに追加


 

STOCKHOLM

Cantargia AB (“Cantargia”) has received approval in Japan and Mexico for its patent application covering IL1RAP as a target molecule for antibody therapy and leukemia diagnostics.

The protection covers treatment and diagnostics of leukemic cancer diseases, and the approval means that Cantargia’s patent will be protected in Japan and Mexico until 2030. Cantargia’s application is now protected in Europe, Japan, South Africa, Mexico and Australia. The corresponding patent applications are being examined by the relevant agencies in the US, China and other countries. Cantargia also has two further patent families related to its CAN04 product candidate.

“Japan is one of the largest markets for pharmaceuticals and this patent approval is of great importance for Cantargia as well as for commercialization of our product candidate CAN04. Mexico is a territory which in addition to its size has a potential of strategic importance for commercialization in neighboring markets. We have thus taken a further step to strengthen the protection around our product candidate CAN04″, CEO Göran Forsberg says.

This information was brought to you by Cision http://news.cision.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160321005422/en/

CONTACT

Cantargia AB
Göran Forsberg, CEO
Telephone: +46 (0)46 275 62 60
E-mail:
goran.forsberg@cantargia.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 美泰上市全球最先进的人参补剂
  • SpinalCyteが新たな日本国特許を取得
  • Together for Safer Roads任命 David Braunstein担任总裁
  • マシモ、rainbow®対応の多派長脈波変動指標となる非侵襲的RPVi™のCEマーク取得を発表
  • Masimo宣布rainbow®多波长脉搏灌注变异指数无创RPVi™获得CE标记